Peer Exchange: Evolving Perspectives and Treatment Strategies in Chronic Spontaneous Urticaria : Episode 7
Opinion
Podcast
Treatment Goals and Guidelines for CSU
Author(s):
Key Takeaways
- Treatment goals are shaped by disease severity, patient preferences, and clinical guidelines, ensuring personalized care.
- Antihistamines are the first-line treatment, with updosing considered for insufficient response by altering dosage or interval.
Panelists discuss the factors influencing the development of treatment goals for chronic spontaneous urticaria (CSU) from both patient and physician perspectives, highlighting current international guidelines that recommend antihistamines as first-line treatment, with options for updosing, and outlining second-line therapies such as omalizumab and third-line options like cyclosporine, along with the recommendation to adjust treatment based on disease control levels.
Video content above is prompted by the following:
- What are the factors that shape the development of treatment goals, both for patients and physicians?
- What do international guidelines currently recommend for therapeutic approach? (Zuberbier, J Allergy Clin Immunol, 2022)
- First-line treatment: antihistamine
- Patients with insufficient response, updosing should be considered, via shortening interview and/or increasing dosage
- Second-line treatment: omalizumab; start with 300 mg/4 weeks
- Third-line treatment: cyclosporine
- General recommendation to step-up and step-down treatment based on levels of disease control
Related Content
